Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;27(5):297-298.
doi: 10.1136/ejhpharm-2020-002322. Epub 2020 Jun 4.

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Tomás Palanques-Pastor  1 , Eduardo López-Briz  2 , José Luis Poveda Andrés  2
Affiliations
Review

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Tomás Palanques-Pastor et al. Eur J Hosp Pharm. 2020 Sep.

Abstract

The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.

Keywords: clinical pharmacy; hospital pharmacy education; immunology; infectious diseases; intensive & critical care.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization Coronavirus disease (COVID-19) outbreak situation. World Health Organization, 2020. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
    1. Centro de Coordinación de Alertas y Emergencias Sanitarias Información científica-técnica: Enfermedad por coronavirus (COVID-19). Ministerio de Sanidad, Consumo y Bienestar Social, 2020. Available: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual...
    1. Sun D, Li H, Lu X, et al. . Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr 2020:1–9. 10.1007/s12519-020-00354-4 - DOI - PMC - PubMed
    1. Mehta P, McAuley DF, Brown M, et al. . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4. 10.1016/S0140-6736(20)30628-0 - DOI - PMC - PubMed
    1. Sarzi-Puttini P, Giorgi V, Sirotti S, et al. . COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 2020;38:337–42. - PubMed